Takeda Ventures senior investment director Ilan Zipkin has become the second high-profile departure from the unit in four months to join the Parker Institute for Cancer Immunotherapy.

Takeda Ventures senior investment director Ilan Zipkin has become the second high-profile departure from the unit in four months to join the Parker Institute for Cancer Immunotherapy.

Opko was among the investors in genetic disease therapy develoepr Eloxx's series C round, which has now been increased by a further $6m to $30m.

LogicBio is developing treatments for orphan paediatric diseases, based on research conducted at Tel Aviv University, Stanford University and Children's Medical Research Institute.

Mitoconix, which is developing neurodegenerative treatments, was founded by the Johnson & Johnson and Takeda-backed FutuRx incubator.

Orkla Ventures was among the investors as medical information portal Your.MD closed a round that will support the deployment of its OneStop Health platform.

Mitoconix is exploiting research into neurodegenerative disorders undertaken by professor Daria Mochly-Rosen and her team at Stanford University.